Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma (MREO) Operating Expenses (2023 - 2025)

Historic Operating Expenses for Mereo BioPharma (MREO) over the last 3 years, with Q3 2025 value amounting to $10.3 million.

  • Mereo BioPharma's Operating Expenses rose 1005.01% to $10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.7 million, marking a year-over-year increase of 1771.14%. This contributed to the annual value of $47.4 million for FY2024, which is 3214.66% up from last year.
  • Per Mereo BioPharma's latest filing, its Operating Expenses stood at $10.3 million for Q3 2025, which was up 1005.01% from $10.9 million recorded in Q2 2025.
  • Over the past 5 years, Mereo BioPharma's Operating Expenses peaked at $15.3 million during Q4 2024, and registered a low of $6.4 million during Q2 2023.
  • Over the past 3 years, Mereo BioPharma's median Operating Expenses value was $10.3 million (recorded in 2025), while the average stood at $10.5 million.
  • The largest annual percentage gain for Mereo BioPharma's Operating Expenses in the last 5 years was 10081.49% (2024), contrasted with its biggest fall of 1579.48% (2024).
  • Quarter analysis of 3 years shows Mereo BioPharma's Operating Expenses stood at $8.4 million in 2023, then skyrocketed by 81.82% to $15.3 million in 2024, then tumbled by 32.47% to $10.3 million in 2025.
  • Its Operating Expenses stands at $10.3 million for Q3 2025, versus $10.9 million for Q2 2025 and $11.2 million for Q1 2025.